Objectives: Our purpose was to evaluate ertapenem versus ceftriaxone/metronidazole for prophylaxis of surgical site infections (SSIs) following elective colorectal surgery in Chinese adult patients.
Introduction
Antibiotic prophylaxis prior to colorectal surgery reduces both the postoperative infection rate and mortality. 1, 2 Ertapenem is a long-acting parenteral 1-b-methyl carbapenem antibiotic characterized by a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative aerobic and anaerobic bacteria. 3 Ceftriaxone sodium is a third-generation cephalosporin extensively studied for use in surgical site infection (SSI) prophylaxis, 4 -7 with reported success rates ranging from 72% to 92%. 5, 8, 9 Adding metronidazole to ceftriaxone can provide coverage for most Gram-positive and Gram-negative aerobic and anaerobic bacteria.
Ertapenem was shown to be more effective than cefotetan, a second-generation cephalosporin, in the prevention of SSIs following colorectal surgery. 10 Subsequent studies showed that the efficacy of ertapenem was similar to that of other commonly used antibiotics 11 and was more cost-effective than cefotetan. 12 In China, antibiotics used for prophylaxis of SSIs for elective colorectal surgery are less standardized, and the continued use of antibiotics after hospital discharge is not uncommon. 13 The purpose of this study was to evaluate the efficacy and safety of ertapenem versus ceftriaxone sodium/metronidazole for prophylaxis of SSIs following elective colorectal surgery in Chinese adult patients.
Methods

Study design
This study was a multicentre, randomized, double-blind, active comparator-controlled clinical trial assessing the non-inferiority of ertapenem against ceftriaxone/metronidazole for the prophylaxis of SSIs in patients undergoing scheduled colorectal surgery (NCT01254344). This study was conducted between December 2010 and December 2011 at 25 sites in China. Merck designed and sponsored the study and collected and analysed the data. The study was conducted in accordance with the guidelines of the International Conference on Harmonization, and was approved by the independent ethics committees at all sites. Written informed consent was obtained from all patients before study screening.
Patients
Patients were qualified for inclusion if they were Chinese adults between 18 and 80 years of age and scheduled to undergo elective colon or colorectal surgery by laparotomy with standard polyethylene glycol bowel preparation. Female patients of reproductive potential were required to abstain from sex or use a suitable birth control method.
Patients were excluded if they required emergency colorectal surgery, had a second surgery anticipated within the 4 week follow-up period, had scheduled laparoscopy-assisted surgery or an isolated rectal procedure, or had revision of a previous operation involving large bowel resection. Also excluded were patients who had active inflammatory bowel disease involving the colon, had bacterial infection requiring systemic antimicrobial therapies within 1 week prior to or at the time of surgery, had a contraindication to the study drugs, had immunosuppression, had neutropenia at screening, were pregnant or lactating, or were considered unlikely to complete the study based on the investigator's judgement.
Treatments
Patients were randomized in a 1 : 1 ratio to one of the two treatment groups via computer-generated blocks by strata based on the planned surgical procedure (stratum I, intraperitoneal procedure; stratum II, abdominoperineal resection), as a difference in risk of SSI between patients who undergo these two procedures has been suggested. 14 The study antibiotic was administered preoperatively by a blinded study nurse, and the investigators were not aware of the group to which the patient was assigned. Patients received either a single 1 g dose of ertapenem followed by a metronidazole-matching placebo (0.9% sodium chloride) or a single 2 g dose of ceftriaxone followed by 500 mg of metronidazole within 2 h prior to the surgical incision. The choice of a 2 g dose of ceftriaxone was based on its pharmacokinetic profile. 5 -9 Each study therapy was administered as a 30 min infusion.
Study endpoint
The primary endpoint of the study was the proportion of patients who had successful prophylaxis of SSI at the 4 week follow-up assessment. The outcome of prophylaxis success was defined as no signs or symptoms of infection at the surgical site, no requirement for further antimicrobial therapy and no surgical intervention for an infection. 15 SSIs were classified as either incisional or organ space. Incisional SSIs were categorized as involving only the skin and subcutaneous tissue (superficial incisional SSI) and those involving deeper soft tissues of the incision (deep incisional SSI). Organ space SSIs were defined as those involving any part of the anatomy (e.g. organ or space) other than incised body wall layers. A prophylactic failure was defined as an incisional infection or organ-space infection. Antibiotics administered for any reason, including for an unexplained or distant infection, within 4 weeks after surgery and anastomotic leakage of the involved bowel requiring additional surgery or antibiotics were also considered failures.
Clinical assessment
Clinical examinations of the abdomen and wound were performed by the study investigators on the day of surgery, every other day during hospitalization, on the day of hospital discharge and at the 4 week follow-up visit. The primary assessment of efficacy was made at the 4 week follow-up visit. If a patient developed an infection at the surgical site or other location, specimens from the site of infection were collected and sent for both aerobic and anaerobic culture at the Department of Laboratory Medicine, Peking Union Medical College Hospital. All organisms considered to be pathogens were tested for in vitro susceptibility to ertapenem and ceftriaxone using the disc diffusion method, while anaerobic organisms were tested for their susceptibility to metronidazole by Etest.
Safety assessment
All patients who received at least a partial dose of the study drug were evaluated for safety. Patients were monitored for clinical and laboratory safety during hospitalization and after discharge. Patients who withdrew from the study were followed for adverse events (AEs) for at least 14 days after the date of discontinuation.
Prespecified safety endpoints consisted of the incidence of any clinical AE, any clinical drug-related AE, any serious AE (SAE), any drug-related SAE and any clinical AE leading to discontinuation.
Statistical analysis: sample size calculation
An estimated sample size of 570 patients for a minimum of 400 clinically evaluable patients (the evaluable population, PP set) would yield 90% power to declare non-inferiority of ertapenem to ceftriaxone/metronidazole, assuming a one-sided 2.5% significance level and a response rate of 70% in each group. 5 -10 The prespecified non-inferiority margin was 215%, based on previous publications, 2,5 -8,10,16 local clinical experience 13 and regulatory agency's perspective.
Analysed populations
The modified ITT (mITT) population consisted of patients who were randomized, received the protocol-specified bowel preparation and surgery and were treated with a complete study dose PP. The evaluable population (PP population) consisted of patients who were randomized, received the protocol-specified bowel preparation and surgery, were treated with a complete study dose PP and did not receive any antibiotics or anti-infective agent prohibited by the protocol. The safety population consisted of all patients who received at least a partial dose of the study drug. For efficacy analyses, data were analysed based on the mITT and PP populations. For the study endpoint, the proportion (point estimate) of patients with successful prophylaxis 4 weeks after treatment who could be evaluated and the associated two-sided 95% CIs were calculated. The CI for the difference in response rates was calculated using the methodology proposed by Miettinen and Nurminen 17 accounting for stratification by the planned surgical procedure. Univariate and multivariate logistic regression analyses with backward elimination selection were applied to identify the association between the incidence of postoperative infection and risk factors in the PP population. Results were represented as ORs with corresponding 95% CIs and P values. The last observation carried forward (LOCF) was only applied for imputing a 'failure outcome' in the primary analysis if the patient was assessed as a prophylaxis failure at any timepoint prior to the 4 week follow-up visit ('failure carried forward').
Baseline characteristics, documented pathogens and clinical AE data are presented as mean+SD for continuous variables or n (%) for Leng et al.
categorical variables. The absolute difference with 95% CI for the clinical AE rate was calculated using Wilson's score method. Differences between groups were compared using the independent two-sample t-test for continuous variables or the x 2 test or Fisher's exact test for categorical ones. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and a value of P≤ 0.05 was considered to indicate statistical significance unless otherwise stated.
Results
Patients
A flow diagram of patient disposition is shown in Figure 1 , and the characteristics of patients that received ertapenem and ceftriaxone/metronidazole are shown in Table 1 . A total of 567 patients completed the study and, based on the analysis criteria, 555 patients qualified for the ITT population (278 in the ertapenem group and 277 in the ceftriaxone group) and 499 for the PP population.
Study endpoint
Outcomes for the primary efficacy endpoint are summarized in Table 2 . In the PP population, adjusted for strata, 90.4% (227/251) of patients in the ertapenem group and 90.3% (224/248) of patients in the ceftriaxone group had successful prophylaxis. The difference in the proportion of patients who had a successful outcome was 0.1% (95% CI 25.2%, 5.5%). In the mITT population, 84.0% (231/275) of patients in the ertapenem group and 82.1% (230/280) of patients in the ceftriaxone group had successful prophylaxis. The difference in the rate was 1.9% (95% CI 24.4%, 8.2). The success rates in the two strata were similar in patients who received ertapenem.
The clinical failure rate was low in both treatment groups (Table 2 ). For the PP population, the most frequent reason for prophylaxis failure in both treatment groups was unexplained antibiotic use [ertapenem 4.8% (12/251); ceftriaxone 4.4% (11/248)].
Microbiological findings
For the PP population, six pathogens were isolated from four patients in the ertapenem group and seven pathogens were isolated from four patients in the ceftriaxone group (Table 3) . The pathogens identified in the mITT population were similar to those seen in the PP population.
Risk factor analysis for postoperative infection
Diabetes mellitus, site shaved/clipped (immediately before surgery versus not performed) and duration of surgery were significantly associated with postoperative infection based on univariate analysis (Table 4) Estimated differences in response are presented as percentages and 95% CIs, which were computed from a statistical model using Cochran-MantelHaenszel weights adjusting for surgical procedure. The method proposed by Miettinen and Nurminen, accounting for stratification by actual surgical procedure, was used to calculate the CI of difference.
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(P¼0.002) were significantly associated with a postoperative infection by multivariate analysis.
Safety analysis
The incidence of clinical AEs was similar between the two groups (Table 5) . No patients in the ertapenem group experienced a drug-related clinical AE, while two patients in the ceftriaxone group did. Twenty patients experienced a clinical SAE (6 in the ertapenem group and 14 in the ceftriaxone group) and none was considered to be drug related. Although the overall incidence of any laboratory AE in both groups was low, a significantly higher incidence was noted in the ceftriaxone group [3.1% (9/297) versus 0.7% (2/290) in the ertapenem group].
Discussion
This multicentre, double-blind comparative clinical study, to our knowledge, is the largest in an Asian population to evaluate the role of antibiotic prophylaxis prior to elective colorectal surgery. The non-inferiority of ertapenem compared with ceftriaxone/ metronidazole in terms of successful prophylaxis was established, based on both PP and ITT analyses. The most frequently occurring reason for failure of prophylaxis was unexplained antibiotic use.
The analysis demonstrated a high rate of successful prophylaxis. This finding is similar to the rate of 92.9% reported by Zanella et al., 9 one Chinese study (88.4%, non-evaluable patients with distant infections included) 18 and one Japanese study (85.8%). 19 The rate of successful outcomes in our study, however, was significantly higher than that in some other studies, 10, 16 though the clinical evaluation criteria were identical. A number of characteristics, including age, weight, nutrition status, tobacco use, preoperative hair removal and surgical factors such as drain use, have been shown to be associated with the development of an SSI after colorectal surgery. 1, 2, 10, 16, 20 An examination of baseline and surgical characteristics indicates that the proportions of patients with certain characteristics, including obesity, diabetes and current tobacco smoking, were significantly lower in our study compared with the US study. 10 Conditions such as diabetes, 1,6,10 obesity 10,16,21 and current tobacco smoking 1, 6, 8 have been demonstrated to inversely affect prophylaxis outcome. Among them, BMI has been shown to be a significant risk factor for prophylaxis failure in a post hoc analysis of the US study data.
10
Nearly one-third of patients enrolled in the US study were obese, whereas only 5% of the patients in the current study had a BMI similar to those of the US study patients. In addition, the use of surgical advances such as wound protectors and supplementary oxygen may have been greater in the current study than in prior studies, and may have provided a benefit with respect to the efficacy of prophylaxis. A similar incidence of SSI was observed in strata I and II in the ertapenem group, which appears to conflict with the findings of previous studies. 10, 14 This finding, however, is difficult to interpret because the overall enrolment of patients in stratum II was significantly lower.
This study had some limitations. Due to a low incidence of prophylaxis failure, only a very small sample of specimens was collected for culture. This precludes evaluation of the relationship between the types of surgical infection and pathogens isolated. Baseline culture of all patients was not part of the study design because this is not routine practice. Thus, the role of specific antibiotic prophylaxis in the community cannot be fully elucidated. Leng et al.
Conclusions
Ertapenem is as effective as ceftriaxone/metronidazole for the prophylaxis of SSIs in patients undergoing elective colorectal surgery. One gram of ertapenem administered intravenously was generally well tolerated when administered as a single dose prior to surgery. Ertapenem prophylaxis of surgical site infections in elective colorectal surgery in China
